Stockscreener 앱 받기
42.08
0.85%
0.115
전일 마감가:
$41.96
열려 있는:
$42.09
하루 거래량:
67,376
Relative Volume:
0.10
시가총액:
$3.30B
수익:
$900.45M
순이익/손실:
$-479.52M
주가수익비율:
-4.8642
EPS:
-8.65
순현금흐름:
$-230.14M
1주 성능:
-0.15%
1개월 성능:
+10.09%
6개월 성능:
+8.93%
1년 성능:
+93.68%
1일 변동 폭
$41.21
$42.66
1주일 범위
$38.26
$42.79
52주 변동 폭
$20.75
$46.98
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PTCT | 42.08 | 3.30B | 900.45M | -479.52M | -230.14M | -8.65 |
| VRTX | 447.24 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.54 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.49 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.58 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.63 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $62.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to Hold at StockNews.com - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 7.4%Time to Sell? - MarketBeat
ARMISTICE CAPITAL, LLC Acquires Additional Shares in PTC Therape - GuruFocus.com
PTC Therapeutics wins FDA nod for gene therapy - MSN
PTC Gets US FDA Approval For Brain-Delivered Gene Therapy - Citeline News & Insights
PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - MedCity News
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain - AOL
AADC deficiency gene therapy, called Kebilidi, now approved in US - AADC News
FDA Approves Eladocagene Exuparvovec-Tneq for Treatment of AADC Deficiency - Pharmacy Times
PTC wins US approval of gene therapy for fatal enzyme disorder - BioPharma Dive
PRV sweetens PTC approval of Kebilidi in AADC deficiency - BioWorld Online
FDA grants accelerated approval for PTC’s AADC deficiency gene therapy - Yahoo Finance
FDA nod for AADC deficiency gene therapy from PTC - The Pharma Letter
PTC Therapeutics' Gene Therapy For AADC Deficiency Approved By FDA - Contract Pharma
PTC Therapeutics wins FDA nod for gene therapy (PTCT:NASDAQ) - Seeking Alpha
PTC Wins First FDA Nod for Direct-to-Brain Gene Therapy, Targets Ultrarare Disease - BioSpace
PTC gets FDA okay for first brain-delivered gene therapy - pharmaphorum
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder - Reuters.com
PTC Therapeutics Wins FDA Approval for Groundbreaking Brain Gene Therapy KEBILIDI | PTCT Stock News - StockTitan
PTC Therapeutics's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com India
Barclays Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript - Insider Monkey
PTC Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $40.38 Average Target Price from Analysts - MarketBeat
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Earnings call: PTC Therapeutics raises 2024 revenue outlook - Investing.com
Wellington Management Group LLP's Strategic Reduction in PTC The - GuruFocus.com
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Re - GuruFocus.com
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Analyst Upgrade - MarketBeat
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $48.00 - MarketBeat
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates - MSN
PTC Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
PTC Therapeutics Reports Strong Q3 2024 Performance - TipRanks
PTC Therapeutics Inc (PTCT) Q3 2024 Earnings: Revenue Surges to $196.8M, Beating Estimates; GAAP EPS at -$1.39 - GuruFocus.com
PTC Therapeutics earnings beat by $0.12, revenue topped estimates - Investing.com UK
PTC Therapeutics Raises 2024 Guidance as Q3 Revenue Hits $196.8M, Pipeline Expands | PTCT Stock News - StockTitan
PTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week HighWhat's Next? - MarketBeat
Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics - MSN
Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
PTC Therapeutics Inc (PTCT) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
PTC Therapeutics to Participate at Upcoming Investor Conferences - StockTitan
PTC Therapeutics resubmitted NDA for Translarna accepted by FDA - MSN
PTC Therapeutics (PTCT) Scheduled to Post Earnings on Thursday - MarketBeat
FDA Accepts Resubmission of Translarna NDA for Duchenne - Managed Healthcare Executive
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighHere's What Happened - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) grows 8.1% this week, taking one-year gains to 127% - Yahoo Finance
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):